You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,265,827

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,265,827

Title:	Anti-PDGFR-beta antibodies and uses thereof
Abstract:	The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with PDGFR-beta signaling and/or PDGFR-beta cellular expression, such as ocular diseases, fibrotic diseases, vascular diseases and cancer.
Inventor(s):	Wiegand; Stanley J. (Hopewell Junction, NY), Lobov; Ivan B. (New York, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	14/148,753
Patent Claims:	1. An isolated antibody or antigen-binding fragment thereof that specifically binds human platelet derived growth factor receptor beta (PDGFR-beta), wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising SEQ ID NOs: 132, 134 and 136, respectively; and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising SEQ ID NOs: 140, 142 and 144, respectively. 2. The isolated antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO:130, and a light chain variable region (LCVR) comprising SEQ ID NO.138. 3. An isolated antibody or antigen-binding fragment thereof that specifically binds monomeric human platelet derived growth factor receptor beta (PDGFR-beta) with a binding dissociation equilibrium constant (K.sub.D) of less than about 200 pM as measured in a surface plasmon resonance assay at 37.degree. C., wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising SEQ ID NOs: 132, 134 and 136, respectively; and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising SEQ ID NOs: 140, 142 and 144, respectively. 4. The isolated antibody or antigen-binding fragment of claim 3, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO:130, and a light chain variable region (LCVR) comprising SEQ ID NO.138. 5. A pharmaceutical composition, comprising: an antibody or antigen-binding fragment thereof that specifically binds monomeric human platelet derived growth factor receptor beta (PDGFR-beta) with a binding dissociation equilibrium constant (K.sub.D) of less than about 200 pM as measured in a surface plasmon resonance assay at 37.degree. C., wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) comprising SEQ ID NOs: 132, 134 and 136, respectively; and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) comprising SEQ ID NOs: 140, 142 and 144, respectively; and a VEGF antagonist wherein the VEGF antagonist is selected from the group consisting of aflibercept, bevacizumab, and ranibizumab; and a pharmaceutically acceptable carrier or diluent. 6. The pharmaceutical composition of claim 5, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO:130, and a light chain variable region (LCVR) comprising SEQ ID NO.138.

Details for Patent 9,265,827

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2033-01-09
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2033-01-09
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2033-01-09
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2033-01-09
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	⤷ Try a Trial	2033-01-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.